A comparison of methods for constructing confidence intervals after phase II/III clinical trials

Kimani, P., Todd, S. ORCID: https://orcid.org/0000-0002-9981-923X and Stallard, N. (2014) A comparison of methods for constructing confidence intervals after phase II/III clinical trials. Biometrical Journal, 56 (1). pp. 107-128. ISSN 0323-3847 doi: 10.1002/bimj.201300036

Abstract/Summary

Recently, in order to accelerate drug development, trials that use adaptive seamless designs such as phase II/III clinical trials have been proposed. Phase II/III clinical trials combine traditional phases II and III into a single trial that is conducted in two stages. Using stage 1 data, an interim analysis is performed to answer phase II objectives and after collection of stage 2 data, a final confirmatory analysis is performed to answer phase III objectives. In this paper we consider phase II/III clinical trials in which, at stage 1, several experimental treatments are compared to a control and the apparently most effective experimental treatment is selected to continue to stage 2. Although these trials are attractive because the confirmatory analysis includes phase II data from stage 1, the inference methods used for trials that compare a single experimental treatment to a control and do not have an interim analysis are no longer appropriate. Several methods for analysing phase II/III clinical trials have been developed. These methods are recent and so there is little literature on extensive comparisons of their characteristics. In this paper we review and compare the various methods available for constructing confidence intervals after phase II/III clinical trials.